Jiang P.-S.,Biomedical Technology and Device Research Laboratory |
Drake P.,Biomedical Technology and Device Research Laboratory |
Cho H.-J.,Biomedical Technology and Device Research Laboratory |
Kao C.-H.,Biomedical Technology and Device Research Laboratory |
And 4 more authors.
Journal of Nanoscience and Nanotechnology | Year: 2012
Gd doped iron-oxide nanoparticles were developed for use in tumour therapy via magnetic fluid hyperthermia (MFH). The effect of the Gd 3+ dopant on the particle size and magnetic properties was investigated. The final particle composition varied from Gd 001Fe 0.99O 4 to Gd 0.04Fe 2.96O 4 as determined by Inductively coupled plasma atomic emission spectroscopy (ICP-AES). TEM image analysis showed the average magnetic core diameters to be 12nm and 33nm for the lowest and highest Gd levels respectively. The specific power adsorption rate (SAR) determined with a field strength of 246 Oe and 52 kHz had a maximum of 38Wg ?1 [Fe] for the Gd 0.03Fe 2.97O 4 sample. This value is about 4 times higher than the reported SAR values for Fe 3O 4. The potential for in vivo tumour therapy was investigated using a mouse model. The mouse models treated with Gd 0.02Fe 0.98O 4 displayed much slower tumour growth after the first treatment cycle, the tumour had increased its mass by 25% after 7 days post treatment compared to a 79% mass increase over the same period for those models treated with standard iron-oxide or saline solution. After a second treatment cycle the mouse treated with Gd 0.02Fe 0.98O 1 showed complete tumour regression with no tumour found for at least 5 days post treatment. Copyright © 2012 American Scientific Publishers All rights reserved. Source